Related references
Note: Only part of the references are listed.Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives
Raghunath Singh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment
Justin Faden et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs
Mingshuo Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect
Mingshuo Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Jakub Staron et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Involvement of 5-HT1A and 5-HT2A Receptors but Not α2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo
Anna Herman et al.
MOLECULAR PHARMACOLOGY (2018)
Brexpiprazole for the treatment of schizophrenia
Wen-Yu Hsu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats
Cedric Mombereau et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2017)
A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment
Jose M. Palacios et al.
PSYCHOPHARMACOLOGY (2017)
Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks
Mohsen Sharifi et al.
BMC BIOINFORMATICS (2017)
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics
Hainimu Xiamuxi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Classics in Chemical Neuroscience: Aripiprazole
Austen B. Casey et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Peng Li et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
An update of safety of clinically used atypical antipsychotics
L. Orsolini et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Polypharmacology of dopamine receptor ligands
S. Butini et al.
PROGRESS IN NEUROBIOLOGY (2016)
Brexpiprazole: so far so good
Saibal Das et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2016)
5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia
Darakhshan J. Haleem
BEHAVIOURAL PHARMACOLOGY (2015)
Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Andrew C. McCreary et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Wei Hu et al.
YEAR IN NEUROLOGY AND PSYCHIATRY (2015)
QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
Mehrul Hasnain et al.
CNS DRUGS (2014)
Olanzapine-Activated AMPK Signaling in the Dorsal Vagal Complex Is Attenuated by Histamine H1 Receptor Agonist in Female Rats
Meng He et al.
ENDOCRINOLOGY (2014)
Hypothalamic histamine HI receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats
Meng He et al.
PSYCHONEUROENDOCRINOLOGY (2014)
Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator
Kenji Maeda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
Katrina Weston-Green et al.
CNS DRUGS (2013)
Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
Pau Celada et al.
CNS DRUGS (2013)
Definition and description of schizophrenia in the DSM-5
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2013)
Designed Multiple Ligands: Basic Research vs Clinical Outcomes
L. Costantino et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Joanne Y. T. Leung et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Antipsychotic Pharmacotherapy and Orthostatic Hypotension Identification and Management
James J. Gugger
CNS DRUGS (2011)
Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Yukihiro Ohno
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis
Surendra P. Singh et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
ROTAROD IMPAIRMENT: CATALEPSY-LIKE SCREENING TEST FOR ANTIPSYCHOTIC SIDE EFFECTS
Katrin M. Kirschbaum et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2009)
Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice
Michel Bourin et al.
PSYCHOPHARMACOLOGY (2009)
Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity
Susanne Jorgensen et al.
JOURNAL OF NEUROSCIENCE METHODS (2008)
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors:: functional receptor-binding and in vivo electrophysiological studies
Arlene D. Stark et al.
PSYCHOPHARMACOLOGY (2007)
Share Paper
